Eye Health Resources
Featured Centers
- Eating Out? Cut Calories, Heartburn
- 5 Good Ways to Save Money on Medicine
- 8 Ways to Treat Your Allergies
|
|
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
NATACYN® (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent ...
Read the complete drug monograph for Natacyn »
Drug Description - Indications & Dosage - Side Effects & Drug Interactions - Warnings & Precautions - Contraindications - Medication Guide and More
What is Patient information?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Serious side effects are not expected with this medication.
Commonly, mild irritation (redness, stinging, or burning) may occur.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Contact your doctor if your symptoms begin to get worse or if you do not see any improvement in your condition after a few days.
Do not touch t...
Read the complete patient information for Natacyn »
Possible Side Effects - Images - What Is - How Should I Take It - What If I Miss a Dose - What Should I Avoid and More
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.